360° SearchNetwork Hot Spots Trends Time Series

hepatocellular carcinoma

Type: Keyphrase

Name: hepatocellular carcinoma

First reported 2 hours ago - Updated 2 hours ago - 1 reports

ITALY: HIV Is No Barrier to Successful Liver Transplant for Cancer Treatment

Research from Italy indicates that HIV infection does not preclude liver transplant as treatment for hepatocellular carcinoma (HCC) and is not a predictor of survival rates after transplant. HCC is the most common type of liver cancer and can be caused ... [Published AEGIS - 2 hours ago]

Entities: HIV/AIDS, Italy, Cancer

First reported 20 hours ago - Updated 20 hours ago - 1 reports

Exelixis Inc

Exelixis Q1 net loss increases

Exelixis, Inc., a biotechnology company, has reported that net loss for the first quarter ended March 31, 2013 was $44.73 million, or $0.24 loss per share, compared to a net loss of $26.15 million, or $0.18 loss per share, for the same quarter ended March ... [Published Individual.com - 20 hours ago]

Entities: Exelixis Inc, Metastatic, renal cell carcinoma

First reported May 20 2013 - Updated 23 hours ago - 2 reports

Bayer Begins Phase III Trial of Stivarga (regorafenib) Tablets in Patients with Advanced Liver Cancer

Bayer HealthCare announced that patient enrollment is underway for RESORCE (Regorafenib after Sorafenib in Patients with Hepatocellular Carcinoma), an international Phase III trial to evaluate the efficacy and safety of Stivarga (regorafenib) tablets ... [Published Individual.com - 23 hours ago]

Entities: Stivarga, regorafenib, Patient, Liver Cancer

First reported May 17 2013 - Updated May 17 2013 - 1 reports

Recent Studies from Harbin Medical University Add New Data to Immunology

(NewsRx) -- By a News Reporter-Staff News Editor at Hepatitis Weekly -- Investigators discuss new findings in Immunology. According to news reporting originating from Heilongjiang, People's Republic of China, by NewsRx correspondents, research stated, ... [Published NewsRX - May 17 2013]

Entities: Immunology, Harbin, Hepatitis B Virus

First reported May 17 2013 - Updated May 17 2013 - 1 reports

What MultiCell Technologies Inc (PINK:MCET) Will Achieve with New Patent Application?

Las Vegas, NV -- (SBWIRE) -- 05/17/2013 -- MultiCell Technologies, Inc. (PINK:MCET) declared that the company is filing an application for U.S. patent for methods and formulations related to targeted tumour cell death. The company said that MCT-485 is ... [Published SBWire - May 17 2013]

Entities: Multicell Technologies Inc, hepatocellular carcinoma, Cancer, Liability, hepatic

First reported May 17 2013 - Updated May 17 2013 - 1 reports

Isis Pharmaceuticals Inc

Isis Pharmaceuticals initiates Phase Ib/IIa hepatocellular carcinoma study

Isis Pharmaceuticals, Inc., a developer of therapeutic drugs inhibiting cell protein synthesis, has initiated a Phase Ib/IIa clinical study of ISIS-STAT3Rx in patients with advanced metastatic hepatocellular carcinoma, or HCC. ISIS-STAT3Rx is an antisense ... [Published Individual.com - May 17 2013]

Entities: hepatocellular carcinoma, Isis Pharmaceuticals Inc, Phase I, Cancer

First reported May 16 2013 - Updated May 16 2013 - 1 reports

World Congress on Interventional Oncology to Present Live TheraSphere® Administration

Interventional Oncology Team at Northwestern Memorial Hospital to performhepatocellular carcinoma liver-directed treatment with live narrationNordion Inc. (TSX: NDN) (NYSE: NDZ),$ a leading provider of products and services for the prevention, diagnosis ... [Published Reuters - May 16 2013]

Entities: Nordion Inc, Oncology, hepatocellular carcinoma, Patient

First reported May 16 2013 - Updated May 16 2013 - 1 reports

11th Month anniversary

. I was diagnosed with Hepatocellular carcinoma (HCC, also called malignant hepatoma). HCC is the most common type of liver cancer. I was given 6 months to live. The only way to beat this was to undergo a liver transplant. The drawback was that the waiting ... [Published StockHouse USA - May 16 2013]

Entities: bile duct, hepatocellular carcinoma, Liver Cancer

First reported May 16 2013 - Updated May 16 2013 - 3 reports

MultiCell Technologies Files U.S. Patent Application for Targeted Delivery of Noncoding Micro RNAs for the Treatment of Liver Cancer

WOONSOCKET, R.I.Hepatocellular carcinoma is the most common form of primary liver cancer, and is a leading cause of cancer death. Hepatocellular carcinoma remains an unmet medical need, and today's approaches for treatment are of limited efficacy. A potential ... [Published Bio-Medicine - May 16 2013]

Entities: Multicell Technologies Inc, Liver Cancer, hepatocellular carcinoma, Tumor, doxorubicin

First reported May 15 2013 - Updated May 16 2013 - 5 reports

Bayer begins phase III trial of regorafenib in patients with hepatocellular carcinoma

Bayer HealthCare, a global enterprise with core competencies in the fields of health care, agriculture and high-tech materials, has started to enroll patients in an international phase III trial to evaluate the efficacy and safety of regorafenib for the ... [Published PharmaBiz - May 16 2013]

Entities: regorafenib, Bayer AG, hepatocellular carcinoma

First reported May 15 2013 - Updated May 15 2013 - 1 reports

Regulus Therapeutics' CEO Discusses Q1 2013 Results - Earnings Call Transcript

Regulus Therapeutics (RGLS) Q1 2013 Earnings Conference Call May 14, 2013 5:00 PM ETOperatorGood afternoon ladies and gentlemen and welcome to the Regulus Therapeutics First Quarter 2013 Conference Call. My name is Jamie and I will be your coordinator ... [Published Seeking Alpha - May 15 2013]

Entities: Regulus Therapeutics, Regulus, hepatocellular carcinoma

First reported May 14 2013 - Updated May 14 2013 - 1 reports

Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection

Hepatitis C Articles (HCV) Back ... [Published National AIDS Treatment Advocacy Project - May 14 2013]

Entities: Entecavir, Hepatitis B Virus, hepatocellular carcinoma

Quotes

...the company's investigational multi-tyrosine kinase inhibitor, lenvatinib, indicated for the treatment of follicular and papillary thyroid cancer. "We are extremely pleased that lenvatinib has received orphan drug designation in the 27 countries of the EU plus Switzerland in the EMEA region. The ODD highlights the unmet need in the treatment of people with radioiodine-refractory differentiated thyroid cancer (RRDTC) and the important potential for this investigational drug. Eisai is dedicated to providing a new option for people with this difficult-to-treat form of the disease" says Gary Hendler, President & CEO Eisai EMEA & Russia...

Eisai receives EU orphan drug designation for thyroid cancer drug [Published Individual.com - 20 hours ago]

"While we continue to execute on the commercial launch, we remain focused on advancing the cabozantinib clinical development program. The majority of sites for the COMET program, consisting of two pivotal trials in CRPC, are now open, and we continue to expect top-line data in 2014. Beyond prostate cancer, we expect to start additional pivotal trials in metastatic renal cell carcinoma (RCC) and metastatic hepatocellular carcinoma (HCC) in the third quarter 2013. In addition, we have a broad and expanding program of earlier stage trials, and updates on some of these trials will be provided at the ASCO Annual Meeting in June."

Exelixis Q1 net loss increases [Published Individual.com - 20 hours ago]

...anofi/Genzyme's Lemtrada? (alemtuzumab) under review in the US and EU for multiple sclerosis Louise Makin, BTG's Chief Executive Officer, commented: "We have delivered strong financial results which reflect the successful transition of our business into a commercially focused, specialist healthcare company that makes and markets its own products. We are on track with our growth strategy, and are investing in our Beads business, preparing for a potential H1 2014 US approval and launch of Varisolve$ and actively seeking opportunities to add new products and programmes. Overall, we have the financial resources and capabilities to continue to build the business and deliver our growth strategy." Andy Burrows, Director of Investor Relations

BTG plc: Final Results [Published Noodls - 20 hours ago]

...in patients with unresectable HCC," said Pamela A Cyrus, MD, Vice President and Head of U S Medical Affairs, Bayer HealthCare Pharmaceuticals. "We look forward to sharing our findings with the scientific community."

Bayer Begins Phase III Trial of Stivarga (regorafenib) Tablets in Patients with Advanced Liver Ca ... [Published Individual.com - 23 hours ago]

More Content

sort by: Date \| Relevance
ITALY: HIV Is No Barrier to Successful Liver Tr... [Published AEGIS - 2 hours ago]
Astex Pharmaceuticals, Inc. Presents at UBS Glo... [Published Seeking Alpha - 7 hours ago]
Isis Pharmaceuticals' Management Presents at UB... [Published Seeking Alpha - 12 hours ago]
Eisai receives EU orphan drug designation for t... [Published Individual.com - 20 hours ago]
Exelixis Q1 net loss increases [Published Individual.com - 20 hours ago]
BTG plc: Final Results [Published Noodls - 20 hours ago]
Bayer Begins Phase III Trial of Stivarga (regor... [Published Individual.com - 23 hours ago]
Bayer Initiates Phase III Trial of Stivarga (re... [Published Drugs.com - May 20 2013]
Will ASCO Unlock Big Value in This Cancer Drug ... [Published Motley Fool Discussion Boards - May 18 2013]
Will ASCO Unlock Big Value in This Cancer Drug ... [Published EquityJungle - v0.1 - May 18 2013]
HIV No Barrier to Getting Liver Transplant, Stu... [Published WebMD - May 17 2013]
Recent Studies from Harbin Medical University A... [Published NewsRX - May 17 2013]
GM Initiates Cadillac Recall, InterOil Gets Off... [Published Wall St. Cheat Sheet - May 17 2013]
GM Initiates Cadillac Recall, InterOil Gets Off... [Published Wall St. Cheat Sheet - May 17 2013]
What MultiCell Technologies Inc (PINK:MCET) Wil... [Published SBWire - May 17 2013]
Isis Pharmaceuticals initiates Phase Ib/IIa hep... [Published Individual.com - May 17 2013]
Stocks in Spotlight - GLOBALGRP INV HLDGS, Mult... [Published SBWire - May 17 2013]
Impact of hepatitis C virus co-infection on HIV... [Published 7thSpace - May 17 2013]
Isis Pharmaceuticals Announces the Initiation o... [Published NewsRX - May 17 2013]
World Congress on Interventional Oncology to Pr... [Published Reuters - May 16 2013]
World Congress on Interventional Oncology to Pr... [Published Business Wire Health News - May 16 2013]
TopStockTips.Com Announces the Hot Stocks for 0... [Published SBWire - May 16 2013]
11th Month anniversary [Published StockHouse USA - May 16 2013]
MultiCell Technologies Files U.S. Patent Applic... [Published Bio-Medicine - May 16 2013]
MultiCell Technologies Files U.S. Patent Applic... [Published Michigan Live - May 16 2013]
MultiCell Technologies Files U.S. Patent Applic... [Published KSWT13 - May 16 2013]
Belinostat resum$er p$ ASCO 2013 [Published Noodls - May 16 2013]
Genome-Wide Transcriptional Reorganization Asso... [Published Elites TV - May 16 2013]
Belinostat abstracts at ASCO 2013 [Published EuroInvestor - May 16 2013]
Belinostat abstracts at ASCO 2013 [Published NASDAQ OMX - May 16 2013]

Blogs

sort by: Date \| Relevance
Will ASCO Unlock Big Value in This Cancer Drug ... [Published EquityJungle - v0.1 - May 18 2013] Filed under: Investing There's little denying that Roche 's cancer wonder drug Avastin has been a godsend to cancer patients and investors alike. Avastin -- which the Food and Drug Administration has approved to treat metastatic colorectal cancer ...
GM Initiates Cadillac Recall, InterOil Gets Off... [Published Wall St. Cheat Sheet - May 17 2013] General Motors ( NYSE:GM ): Efforts to take the Chinese market by storm and gain an edge over competition has hit some headwinds , as Cadillac China initiates a recall for 2,653 imported SRX crossover models, due to a wheel nut issue. It is not yet ...
GM Initiates Cadillac Recall, InterOil Gets Off... [Published Wall St. Cheat Sheet - May 17 2013] General Motors ( NYSE:GM ): Efforts to take the Chinese market by storm and gain an edge over competition has hit some headwinds , as Cadillac China initiates a recall for 2,653 imported SRX crossover models, due to a wheel nut issue. It is not yet ...
Jennerex Granted FDA Orphan Drug Designation fo... [Published News from Kidney Cancer Association - May 09 2013] Jennerex, Biotherapeutics, Inc., a private, clinical-stage biotechnology company focused on the development and commercialization of best-in-class targeted oncolytic immunotherapies for solid tumors, today announced that the United States Food and Drug ...
Exelixis Earnings: Here’s Why the Stock is Up Now [Published Wall St. Cheat Sheet - May 07 2013] Exelixis, Inc. ( NASDAQ:EXEL ) had a loss and beat Wall Street’s expectations, AND beat the revenue expectation. The revenue beat is a positive sign to shareholders seeking high growth out of the company. Shares are up 0.02%.Markets are at 5-year highs! ...

Audio/Video

sort by: Date \| Relevance
The Nathan Bass UCSF Liver - Management of Hepa... [Published UC Television - YouTube - Mar 14 2013]

Press Releases

sort by: Date \| Relevance
World Congress on Interventional Oncology to Pr... [Published Business Wire Health News - May 16 2013]
Bayer Initiates Phase III Trial of Stivarga® (r... [Published PR Newswire: Health - May 15 2013]
Jennerex Granted FDA Orphan Drug Designation fo... [Published Marketwire - Breaking News Releases - May 08 2013]
Exelixis Announces First Quarter 2013 Financial... [Published Business Wire - May 07 2013]
Isis Pharmaceuticals Announces the Initiation o... [Published PR Newswire: Health - May 06 2013]